# SenesTech, Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [SenesTech, Inc.](/companies/snes.md) (CIK 1680378)
- Form: 10-Q
- Filed: 2018-11-14
- Accepted by EDGAR: Nov 14, 2018, 07:02 ET
- Period: 2018-09-30
- Accession: 0001615774-18-012611
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1680378/000161577418012611/s113874_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1680378/000161577418012611/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $114.0k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $153.0k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2018-07-01 to 2018-09-30 | −$9.0k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-01-01 to 2018-09-30 | $7.0k | us-gaap:GrossProfit |
| Research and development | 3 months, 2018-07-01 to 2018-09-30 | $476.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2018-01-01 to 2018-09-30 | $1.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | −$9.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | −$2.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | −$9.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.14 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | −$0.53 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | −$6.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $212.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2018-09-30 | $4.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $8.8m | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $9.9m | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $972.0k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $1.3m | us-gaap:Liabilities |
| Long-term debt | at 2018-09-30 | $296.0k | us-gaap:LongTermDebt |
| Current portion of debt | at 2018-09-30 | $235.0k | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2018-09-30 | $235.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2018-09-30 | $8.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 45,617 characters.

As used in this Quarterly Report on Form 10-Q, “SenesTech,” the “Company,” “we,” “us,” or “our” refer to SenesTech, Inc., a Delaware corporation.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our condensed consolidated financial statements and related notes. Some statements and information contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, notes to our condensed consolidated financial statements and elsewhere in this report are not historical facts but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, readers can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology, which when used are meant to signify the statement as forward-looking. These forward-looking statements include, but are not limited to, our expectations regarding new accounting standards on our financial results, our expectations regarding our critical accounting policies; our expectations regarding our current operating plan, including operating expenses, product sales and revenue expectations, profitability and cash flows, our beliefs regarding the use of stock-based awards as a compensation tool, our beliefs regarding certain tax positions, our beliefs regarding our revenue targets and the sufficiency of our liquidity and capital resources, our beliefs regarding ongoing litigation, our expectations regarding our significant employees, our expectations regarding commercialization of ContraPest and product development of our other product candidates, our expectations regarding our sales channel, including distributors, our expectations regarding regulatory approval of our products or product candidates, the continued listing of our common stock on The Nasdaq Capital Market, statements about our plans, objectives, expectations and intentions and other statements that are not historical facts. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and situations that are difficult to predict and that may cause our own, or our industry’s actual results, to be materially different from the future results that are expressed or implied by these statements. Accordingly, actual results may differ materially from those anticipated or expressed in such statements as a result of a variety of factors, including those discussed in Item 1A of Part II of this Report, entitled “Risk Factors,” and those contained from time to time in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

### Overview

Since our inception in 2004, we have devoted substantially all of our resources to organizing and staffing our company, conducting research and development activities for our product candidates, business planning, raising capital and acquiring and developing product and technology rights. Until August 2016, we did not have any products approved for sale, and we have generated minimal revenue from product sales to date. We have primarily funded our operations to date with proceeds from the sale of common stock and preferred stock, the issuance of convertible and other promissory notes and, to a lesser extent, payments received in connection with research grants and licensing fees. Through September 30, 2018, we had received net proceeds of $61.7 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $0.2 million in product sales. At September 30, 2018, we had an accumulated deficit of $83.2 million and cash and cash equivalents and highly liquid investments of $7.2 million.

We have incurred significant operating losses every year since our inception. Our net losses were $2.5 million, $9.3 million and $2.9 million and $10.0 million for the three and nine months ended September 30, 2018 and September 30, 2017, respectively. As of September 30, 2018, we had an accumulated deficit of $83.2 million. We expect to continue to incur significant expenses and generate operating losses for at least the next 12 months.

We have historically utilized, and intend to continue to utilize, various forms of stock-based awards in order to hire, retain and motivate talented employees, consultants and directors and encourage them to devote their best efforts to our business and financial success. In addition, we believe that our ability to grant stock-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders.

As a result, a significant portion of our operating expenses includes stock-based compensation expense. Stock-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy. Specifically, our stock-based compensation expense for the nine months ended September 30, 2018 and September 30, 2017, was $3.1 million and $2.8 million, respectively, which represented 32.2% and 28.1%, respectively, of our total operating expenses for those periods.

### Components of our Results of Operations

### Net Sales

We recognized net product sales of $105,000 and $17,000 for the three months ended September 30, 2018 and 2017, respectively, and $160,000 and $34,000 and for the nine months ended September 30, 2018 and 2017, respectively. The increase in our net product sales was a result of increased sales of ContraPest to our distributors. Prior to 2017, all of our revenue was derived from payments received in connection with research grants and licensing fees received under the former license agreement with Neogen. We recognized $0 revenue for the three and nine months ended September 30, 2018 and September 30, 2017, respectively, for services performed under NIH grants and in licensing fees under our former license agreement with Neogen. We do not anticipate additional grant revenue under the NIH grants or additional revenue from our former license agreement with Neogen.

### Operating Expenses

#### Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with the research and development of ContraPest and our other product candidates, which include:

- Employee related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
- Expenses incurred in connection with the development of our product candidates; and
- Facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies.

We expense research and development costs as incurred.

We continue to investigate other applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates. At this time, we cannot reasonably estimate the costs for further development of ContraPest or the cost associated with the development of any of our other product candidates.

We plan to continue to hire employees to support our research and development efforts and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain employees for our research and development efforts. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our research and development expenses for the foreseeable future.

#### Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, sales, marketing and administrative functions. Selling, general and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, consulting, accounting and audit services.

We anticipate that our selling, general and administrative expenses may increase in the future as we increase our headcount to support commercialization of ContraPest and further development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated with being a public company.

We plan to continue to hire employees to support our commercialization of ContraPest and further development of our product candidates and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain qualified employees. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our selling, general and administrative expenses for the foreseeable future.

*Interest Income*. Interest income consists primarily of interest income earned on cash and cash equivalents. Prior to 2017, our interest income has not been significant due to nominal cash and investment balances and low interest earned on invested balances. For the three months and nine months ended September 30, 2018, we recorded $1,000 and $8,000 of interest income on our cash and short term, highly liquid investments, respectively, compared to $9,000 and $20,000 for the three months and nine months ended September 30, 2017, respectively. The decrease in interest income was primarily due to a decrease in average investments as monies previously invested were used for operating expenses.

*Interest Expense*. Interest expense for the nine months ended September 30, 2018 and September 30, 2017 consists primarily of interest accrued on our capital lease and note commitments. For the three months and nine months ended September 30, 2018, we recorded $16,000 and $60,000 of interest expense, respectively, compared to $33,000 and $54,000 for the three months and nine months ended September 30, 2017, respectively. The decrease in interest expense for the three months ended September 30, 2018 compared to the same period in 2017 was due to a reduction of notes payable as a result of the sale of a vehicle in April 2018 and the proceeds used to paydown the related notes payable. The increase in interest expense for the nine months ended September 30, 2018 compared to the same period in 2017 was a result of an increase in equipment financing note commitments in the last six months of 2017 for asset acquisitions.

*Other Income (Expense), Net*. Other income (expense), net, consists primarily of recognized change in value of short-term investments and income (expense) related to the year-over-year fair market value adjustment of our derivative warrant and losses associated with the early extinguishment of debt. We recorded other income, net of $13,000 and $19,000 for the three and nine months ended September 30, 2018, respectively, compared to other income of $37,000 and $76,000 for the three months and nine months ended September 30, 2017, respectively. The decrease in other income was primarily due to a $10,000 loss on extinguishment of debt and less fluctuation in the fair market value of our derivative warrant resulting in less income from reduced derivative warrant liability.

#### Income Taxes

Deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate for the three and nine months ended September 30, 2018 and the year ended December 31, 2017 has been affected by the valuation allowance on the Company’s deferred tax assets.

Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of September 30, 2018, we had federal net operating loss carryforwards of $51.7 million which begin to expire in 2023 and state net operating loss carryforwards of $40.9 million which began to expire in 2016, unless utilized.

### Comparison of the Three and Nine Months Ended September 30, 2018 and 2017

The following table summarizes our results of operations for the three and nine months ended September 30, 2018 and 2017:

### STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

### (In thousands, except shares and per share data)

### (Unaudited)

|  | For the Three Months Ended September 30, 2018 | 2017 | For the Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net Sales | $105 | $17 | $160 | $34 |
| Cost of sales | 114 | 11 | 153 | 27 |
| Gross profit (loss) | (9) | 6 | 7 | 7 |
| Operating expenses: |  |  |  |  |
| Research and development | 476 | 721 | 1,746 | 2,517 |
| Selling, general and administrative | 2,013 | 2,235 | 7,506 | 7,506 |
| Total operating expenses | 2,489 | 2,956 | 9,252 | 10,023 |
| Net operating loss | (2,498) | (2,950) | (9,245) | (10,016) |
| Other income (expense): |  |  |  |  |
| Interest income | 1 | 9 | 8 | 20 |
| Interest expense | (16) | (33) | (60) | (54) |
| Interest expense, related parties | — | — | — | (1) |
| Other income (expense) | 13 | 37 | 19 | 76 |
| Total other income (expense) | (2) | 13 | (33) | 41 |
| Net loss and comprehensive loss | $(2,500) | $(2,937) | $(9,278) | $(9,975) |
| Warrant andtdilution price protection adjustment | 333 | — | 333 | — |
| Net loss attributable to common shareholders | $(2,833) | $(2,937) | $(9,611) | $(9,975) |
| Loss per share atrributable to common shareholders, basic and diluted | $(0.14) | $(0.28) | $(0.53) | $(0.97) |
| Weighted average common shares outstanding - basic and fully diluted | 20,862,216 | 10,334,211 | 18,036,982 | 10,234,211 |

See accompanying notes to financial statements.

### Three Months Ended September 30, 2018 compared to Three Months Ended September 30, 2017:

#### Net Sales

Net sales were $105,000 for the three months ended September 30, 2018, compared to $17,000 for three months ended September 30, 2017.

The increase in our net product sales of $88,000 was a result of increased sales of ContraPest to our distributors as a result of increased marketing efforts and sales promotions. Sales for the three months ended September 30, 2018 are shown net of sales discounts and promotions. We expect net product sales to continue to increase quarter over quarter for the foreseeable future.

#### Cost of Goods Sold

Cost of goods sold was $114,000 for the three months ended September 30, 2018, compared to $11,000 for three months ended September 30, 2017. The increase in cost of goods sold, was a driven by the cost of increased sales as well as increased scrap related to product manufactured during scale up activities that were ultimately deemed unsellable, partially offset by process improvement efficiencies. We anticipate cost of goods sold as a % of sales will improve for the foreseeable future due to manufacturing efficiencies as a result of the scale up activities.

#### Gross Profit (Loss)

Gross loss for the three months ended September 30, 2018 was ($9,000) or (8.6%) of net sales, compared to a gross profit of $6,000 or 35.5% of net sales,for the three months ended September 30, 2017. The decrease in gross profit was a direct result of increased sales discounts and promotions as well as increased scrap related to scale up activities.

#### Research and Development Expenses

*(in thousands)*

| Research and development expenses: Unallocated expenses: | Three Months Ended September 30, 2018 | 2017 | Increase / (Decrease) |
| --- | ---: | ---: | ---: |
| Personnel related (including stock-based compensation) | $365 | $449 | $(84) |
| Professional Fees/Consultants | 1 | 39 | (38) |
| Facility related | 58 | 76 | (18) |
| Other | 52 | 157 | (105) |
| Total research and development expenses | $476 | $721 | $(245) |

Research and development expenses were $476,000 for the three months ended September 30, 2018, compared to $721,000 for the same period in 2017. The $245,000 decrease in research and development expenses was primarily due to a decrease of $38,000 in professional fees/consultant expenses, a decrease in personnel-related costs of $84,000, a decrease in facility expenses of $18,000 and a decrease in other expenses of $105,000. The decrease in personnel-related costs resulted from an increase in research and development salaries and related benefits and taxes of $139,000 due to additional headcount offset by a decrease in stock-based compensation expense of $55,000. Professional services and consulting expenses decreased $38,000 for the three months ended September 30, 2018, compared to the same period in 2017 primarily due to a decrease in synthetic triptolide research fees and legal fees associated with regulatory approval. Rent and utilities for the three months ended September 30, 2018 decreased $18,000 over the same period in 2017 due primarily to a decrease in rent expense. Other expenses decreased by $105,000 to $52,000 for the three months ended September 30, 2018 as compared to $157,000 for the same period in 2017, primarily due to decreased travel expenses of $20,000 related to reduced field team on-site evaluations of potential customers and research operations, decreased depreciation expense of $63,000, lower lab fees of $12,000 and reduced office and supplies expenses of $10,000.

We continue to investigate applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates.

#### Selling, General and Administrative Expenses

Selling, general and administrative expenses were $2.0 million for the three months ended September 30, 2018, compared to $2.2 million for the three months ended September 30, 2017. The decrease of $0.2 million in selling, general and administrative expenses was primarily due to a decrease of $671,000 in personnel related expenses, offset by an increase of $55,000 in legal expenses as a result of ongoing litigation, $65,000 increase in consulting expenses primarily related to software implementation consultants and tax and professional consulting, $19,000 in insurance expenses related to the increased D&O insurance expense, an increase in trade show and marketing expenses of $70,000 due to the commercialization of ContraPest and new website design expenses, an increase of $24,000 in travel expenses, an increase of $55,000 in professional services expenses due to increased contracted research fees and an increase in depreciation expense of $73,000. The decrease in personnel related expenses consisted of a decrease in stock-based compensation of $536,000 and a decrease of $135,000 in net salary costs due to reduced payroll taxes associated with net settlement tax expense and non-inducement grant stock compensation.

#### Interest Expense

We recorded $15,000 of interest expense, net for the three months ended September 30, 2018, compared to $24,000 for the same period in 2017. The decrease in interest expense of $9,000 was the result of decreased debt in the form of notes payable due primarily to the sale of a vehicle and related debt reduction in April 2018.

#### Other Income (Expense), Net

We recorded $13,000 of other income, net for the three months ended September 30, 2018, compared to $37,000 of other income for the same period in 2017. The $24,000 net decrease in other income was primarily due to lower income recognized for year-over-year fair market value adjustment of our convertible promissory notes a $10,000 loss on the early extinguishment of a note payable.

***Nine Months Ended September 30, 2018 compared to Nine Months Ended September 30, 2017:***

#### Net Sales

Net sales were $160,000 for the nine months ended September 30, 2018, compared to $34,000 for three months ended September 30, 2017.

The increase in our net product sales of $126,000 was a result of increased sales of ContraPest to our distributors as a result of increased marketing efforts and sales promotions.

#### Cost of Goods Sold

Cost of goods sold was $153,000 for the nine months ended September 30, 2018, compared to $27,000 for nine months ended September 30, 2017. The increase in cost of goods sold was a direct result of the cost of increased sales and increased scrap related to scale up activities and stock product ultimately deemed unsellable during the quarter ended September 30, 2018.

#### Gross Profit

Gross profit for the nine months ended September 30, 2018 was $7,000 or 4.4% of net sales, compared to a gross profit of $7,000 or 20.6% of net sales for the nine months ended September 30, 2017. The decrease in gross profit as a % of net sales was a direct result of increased sales discounts and promotions as well as increased scrap related to scale up activities in the period ended September 30, 2018.

#### Research and Development Expenses

*(in thousands)*

| Direct research and development expenses: Unallocated expenses: | Nine Months Ended September 30 2018 | 2017 | Increase/ (Decrease) |
| --- | ---: | ---: | ---: |
| Personnel related (including stock-based compensation) | $1,124 | $1,471 | $(347) |
| Professional Fees/Consultants | 22 | 272 | (250) |
| Facility related | 172 | 228 | (56) |
| Other | 428 | 546 | (118) |
| Total research and development expenses | $1,746 | $2,517 | $(771) |

Research and development expenses were approximately $1.7 million for the nine months ended September 30, 2018, compared to approximately $2.5 million for the same period in 2017. The $800,000 decrease in research and development expenses was partially due to a decrease of $347,000 in personnel-related costs. This decrease in personnel-related costs resulted from decreased research and development salaries of $165,000 due to headcount additions in the fourth quarter of 2017 and a decrease in stock-based compensation expense of $182,000. Professional services and consulting expenses decreased $250,000 for the nine months ended September 30, 2018 compared to the same period in 2017 primarily due to lower synthetic triptolide research fees and legal fees. Facilities expenses for the nine months ended September 30, 2018 were lower than the same period in in 2017 by $56,000 due to the termination of a lease on the east coast for field operations. Other expenses for the nine months ended September 30, 2018 were lower by $197,000 primarily due to a reduction of supplies and maintenance expenses.

We continue to investigate applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates.

#### Selling, General and Administrative Expenses

Selling, general and administrative expenses were $7.5 million for the nine months ended September 30, 2018 and for the nine months ended September 30, 2017. Personnel related expenses for the nine months ended September 30, 2018 decreased by $138,000 offset by increased insurance expenses, primarily director and officer insurance and depreciation expenses of $138,000. The decrease in personnel related expenses was the result of an increase in stock-based compensation of $453,000, primarily due to stock compensation expense related to the issuance of inducement warrants to an investor in June 2018, offset by a decrease of $115,000 in recruiting expenses and a decrease of $476,000 in payroll taxes, reflecting lower net settlement tax charges.

#### Interest Expense

We recorded $52,000 of interest expense, net for the nine months ended September 30, 2018, compared to $34,000 for the same period in 2017. The increase in interest expense of $18,000 was the result of an increase in equipment financing note commitments in the last six months of 2017 for asset acquisitions.

#### Other Income (Expense), Net

We recorded $19,000 of other income, net, for the nine months ended September 30, 2018, compared to $76,000 of other expense for the same period in 2017. The $57,000 net decrease in other income was primarily due to lower income recognized for year-over-year fair market value adjustment of our convertible promissory notes a $10,000 loss on the early extinguishment of a note payable in the nine months ended September 30, 2018.

### Liquidity and Capital Resources

Since our inception, we have sustained significant operating losses in the course of our research and development activities and commercialization efforts,and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began full scale marketing of our first product, ContraPest, and we continue to develop other product candidates, which are in various phases of development. We have funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock, debt financing, consisting primarily of convertible notes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees. Through September 30, 2018, we had received net proceeds of $61.7 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, and an aggregate of $1.7 million from licensing fees and an aggregate of $0.2 million from product sales. At September 30, 2018, we had an accumulated deficit of $83.2 million and cash and cash equivalents and highly liquid investments of $7.2 million.

Our ultimate success depends upon the outcome of a combination of factors, including: (i) successful commercialization of ContraPest and ongoing regulatory approval of our other product candidates; (ii) market acceptance, commercial viability and profitability of ContraPest and other products; (iii) the ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs.

Based upon our current operating plan, we expect that cash and cash equivalents and highly liquid, short term investments at September 30, 2018, in combination with anticipated revenue, will be sufficient to fund our current operations for at least the next 12 months. However, if anticipated revenue targets and margin targets are not achieved, we may seek to reduce operating expenses and are likely to require additional capital in order to fund our operating losses and research and development activities until we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will need to continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate development and commercialization efforts.

### Additional Funding Requirements

We expect our expenses to increase in connection with our ongoing activities, particularly as we market and focus on sales of ContraPest, and as we advance field studies of our product candidates in development. In addition, we will continue to incur costs associated with operating as a public company.

In particular, we expect to incur substantial and increased expenses as we:

- Work to maximize market acceptance for, and generate sales of, our products;
- Manage the infrastructure for the sales, marketing and distribution of ContraPest and any other product candidates for which we may receive regulatory approval;
- Continue the development of ContraPest and our other product candidates, including engaging in any necessary field studies;
- Seek additional regulatory approvals for ContraPest and our other product candidates;
- Scale up manufacturing processes and quantities to meet future demand of ContraPest and any other product candidates for which we receive regulatory approval;
- Continue product development of ContraPest and advance our research and development activities and advance the research and development programs for other product candidates;
- Maintain, expand and protect our intellectual property portfolio; and
- Add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company.

### Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

|  | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: |
| Cash used in operating activities | $(6,916) | $(7,596) |
| Cash provided by (used in) investing activities | 2,592 | (3,825) |
| Cash provided by financing activities | 7,014 | 294 |
| Net increase (decrease) in cash and cash equivalents | $2,690 | $(11,127) |

35

#### Operating Activities

During the nine months ended September 30, 2018, operating activities used $6.9 million of cash, primarily resulting from our net loss of $9.3 million and by changes in our operating assets and liabilities of $1.1 million, partially offset by non-cash charges of $3.4 million, consisting primarily of stock-based compensation, depreciation and amortization. Our net loss was primarily attributable to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash used by changes in our operating assets and liabilities for the nine months ended September 30, 2018 consisted primarily of an increase in inventory of $578,000, prepaid expenses of $166,000, a decrease in accounts payable/accrued expenses of $251,000, an increase in receivables of $36,000 and a decrease in deferred rent of $18,000, offset by a decrease in deposits of $7,000.

During the nine months ended September 30, 2017, operating activities used $7.6 million of cash, primarily resulting from our net loss of $10.0 million and by changes in our operating assets and liabilities of $0.6 million, partially offset by non-cash charges of $3.0 million. Our net loss was primarily attributed to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash used by changes in our operating assets and liabilities for the nine months ended September 30, 2017 consisted primarily of a decrease in prepaid expenses of $165,000 and a decrease in receivables of $3,000 and an increase in deferred rent of $12,000, offset by a net decrease in accrued expenses and accounts payable of $473,000, a net increase in inventories of $337,000 and an increase in deposits of $8,000. The net decrease in accrued expenses and accounts payable was primarily due to timing of expense occurrence and payables management, offset by our payment of the $1.0 million contract cancellation settlement accrual in January.

#### Investing Activities

For the nine months ended September 30, 2018, net cash of $2.6 million was provided by investing activities consisting of $2.6 million of proceeds received from the sale of securities and $185,000 of proceeds from the sale of equipment offset by $212,000 in purchases of property and equipment.

For the nine months ended September 30, 2017, we used $3.8 million in investing activities consisting of $2.9 million of purchases in securities and $885,000 in purchases of property and equipment.

#### Financing Activities

During the nine months ended September 30, 2018, net cash provided by financing activities was $7.0 million as a result of $5.1 million in proceeds from the issuance of common stock, net, $2.2 million in proceeds from warrant exercises and $9,000 in proceeds from issuances of notes, offset by $248,000 of repayments of related to notes payable and notes payable, related party, $50,000 in repayments of capital lease obligations and $42,000 of payments for employee withholding taxes related to share-based awards.

During the nine months ended September 30, 2017, net cash generated from financing activities was $294,000 as a result of $437,000 of proceeds from the issuance notes payable offset by payments of $66,000 related to notes payable and notes payable related party and $77,000 in payments of capital lease obligations.

### Off-Balance Sheet Arrangements

As of September 30, 2018, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K.

### Recent Developments

On September 26, 2018, we received a letter from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) providing notification that the bid price for our common stock had closed below $1.00 per share for the previous 30 consecutive business days and our common stock no longer met the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have an initial period of 180 calendar days, or until March 25, 2019, to regain compliance. To regain compliance, the closing bid price of our common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before March 25, 2019.

If we do not regain compliance with Rule 5550(a)(2) by March 25, 2019, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and would need to provide written notice of our intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq would notify us that our securities would be subject to delisting. In the event of such notification, we may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant our request for continued listing.

The Nasdaq notification has no immediate effect on the listing of our common stock on the Nasdaq Capital Market. We intend to actively monitor the bid price of our common stock and its minimum market value of listed securities and will consider options available to us to achieve compliance with the Nasdaq listing rules, including effecting a reverse stock split, if necessary. There can be no assurance that we will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market.

### Critical Accounting Policies and Significant Judgments and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 — Summary of Significant Accounting Policies to our financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.

### Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.

There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the three months ended and nine months ended September 30, 2018 and 2017, or the twelve months ended December 31, 2017.

### Stock-Based Compensation

We recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures, in accordance with ASC Topic 718 — *Stock Compensation (“*ASC 718”). We estimate the grant date fair value of the awards, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective award. We account for stock-based compensation arrangements with non-employees using a fair value approach. The fair value of these stock options is measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected life, which is assumed to be the remaining contractual life of the option. The fair value of the stock options granted to non-employees is re-measured as the stock options vest and is recognized in the statements of operations and comprehensive loss during the period the related services are rendered.

We recorded stock-based compensation expense of approximately $355,000 and $3.1 million for the three and nine months ended September 30, 2018, respectively and $1.0 million and $2.8 million for the three and nine months ended September 30, 2017, respectively. We expect to continue to grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase.

The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and loss per share of common stock could have been significantly different. Our assumptions are as follows:

- *Expected term.* The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, we estimate the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
- *Expected volatility.* Expected volatility is derived from the average historical volatilities of publicly traded companies within our industry that we consider to be comparable to our business over a period approximately equal to the expected term. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation.
- *Risk-free interest rate.* The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
- *Expected dividend.* The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.
- *Expected forfeitures.* We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.

#### Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock

As noted above, we are required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model. Before the consummation of our initial public offering, and in the absence of an active market for our common stock, we utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, *Valuation of Privately-Held Company Equity Securities Issued as Compensation*, to estimate the fair value of our common stock.

The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. If we had made different assumptions than those used, the amount of our stock-based compensation expense, net income and net income per share amounts could have been significantly different. The fair value per share of our common stock for purposes of determining stock-based compensation expense is the closing price of our common stock as reported on the applicable grant date. The compensation cost that has been included in the statements of operations and comprehensive loss for all stock-based compensation arrangements is as follows:

|  | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Research and development | $29 | $85 | $87 | $269 |
| Selling, general and administrative | 326 | 861 | 3,003 | 2,549 |
| Total stock-based compensation expense | $355 | $946 | $3,090 | $2,818 |

39

The intrinsic value of stock options outstanding as of September 30, 2018 was $0.

### Emerging Growth Company Status

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we intend to comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.

## Controls and procedures

As filed, 1,618 characters.

### Evaluation of Disclosure Controls and Procedures

We conducted an evaluation (pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”)), under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e)) as of the end of the period covered by this report. These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that this information is accumulated and communicated to management, including the principal executive and principal financial officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2018, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 4,236 characters.

The risks described in our Annual Report on Form 10-K, as amended, for the year ended December 30, 2017 (the “2017 Annual Report”), and our Quarterly Report on Form 10-Q for the period ended June 30, 2018 (the “Q2 Quarterly Report”) could materially and adversely affect our business, financial condition, results of operations and the trading price of our securities. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and financial results. Below we have updated a risk factor included in the Q2 Quarterly Report to supplement the risks described in the 2017 Annual Report and the Q2 Quarterly Report.

***We may not be able to comply with all applicable listing requirements or standards of The Nasdaq Capital Market and Nasdaq could delist our common stock.***

Our common stock is listed on the Nasdaq Capital Market. In order to maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards. On September 26, 2018, we received a deficiency letter from the listing qualifications staff of the Nasdaq Stock Market, notifying us that, for the prior 30 consecutive business days, the closing bid price of our common stock was not maintained at the minimum required closing bid price of at least $1.00 per share as required for continued listing on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rules, we have an initial compliance period of 180 calendar days, until March 25, 2019, to regain compliance with this requirement.

In the event that we are unable to increase our stock price above $1 per share to regain compliance with NASDAQ listing requirements, we may be required to complete a reverse stock split. Our stockholders approved an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock, by a ratio of not less than one-for-two shares and not more than one-for-five shares. Our board of directors may complete a reverse stock split at any time prior to the date of our 2019 Annual Meeting of Stockholders at a ratio to be set within the range of ratios previously approved by the stockholders.

In the event that we are unable to regain compliance with the applicable NASDAQ listing requirements or standards of The NASDAQ Capital Market, our common stock could be delisted from The NASDAQ Capital Market, which could have a material adverse effect on our financial condition and which could cause the value of our common stock to decline. If our common stock is not eligible for listing or quotation on another market or exchange, trading of our common stock could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely be a reduction in our coverage by security analysts and the news media, which could cause the price of our common stock to decline further. In addition, it may be difficult for us to raise additional capital if we are not listed on a major exchange.

We cannot provide any assurance that stock price will regain the minimum bid price requirements of Nasdaq or that we will be able to satisfy any other continued listing requirement of the Nasdaq Stock Market. In the event that our common stock is not eligible for quotation on another market or exchange, trading of our common stock could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely be a reduction in our coverage by security analysts and the news media, which could cause the price of our common stock to decline further. In addition, it may be difficult for us to raise additional capital if we are not listed on a major exchange.

Filed Nov 14, 2018.
Source: SEC EDGAR, the filing index for accession 0001615774-18-012611. Last ingested by Listed: Nov 14, 2026, 18:52 ET. No prices; not investment advice.
